Australia's Therapeutic Goods Administration has removed Andrographis paniculata from the ingredients permitted in low-risk listed medicines after reviewing the risk of serious allergic reactions.
The change took effect on September 17, meaning new medicines containing Andrographis can no longer enter the Australian Register of Therapeutic Goods through the listed-medicine pathway. A registered-medicine application remains possible but requires assessment of safety, quality and effectiveness.
Existing listed products may remain temporarily, but the TGA says sponsors are strongly encouraged to cancel their listings, stop supply and conduct a consumer-level recall. The regulator may begin case-by-case action from mid-October if sponsors do not act.
This is not an immediate blanket recall of every product. Consumers should check product labels and current TGA notices, and seek urgent medical help for symptoms of anaphylaxis or another severe allergic reaction.
Sources: Therapeutic Goods Administration, September 2026; ABC News, 22 September 2026.
Image disclosure: The featured image is an AI-generated consumer-safety illustration using generic unbranded containers and plants. It does not show a specific medicine, recalled product or regulatory notice.
